Business Description
Lytix Biopharma AS
ISIN : NO0010405780
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 20.08 | |||||
Equity-to-Asset | 0.76 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.04 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | 9.07 | |||||
Beneish M-Score | 0.46 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -25.9 | |||||
3-Year EPS without NRI Growth Rate | -26.3 | |||||
3-Year FCF Growth Rate | -56.1 | |||||
3-Year Book Growth Rate | 35.7 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 35.21 | |||||
9-Day RSI | 30.66 | |||||
14-Day RSI | 31.73 | |||||
6-1 Month Momentum % | 43.75 | |||||
12-1 Month Momentum % | 40.46 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.61 | |||||
Quick Ratio | 4.61 | |||||
Cash Ratio | 3.72 | |||||
Days Sales Outstanding | 218.45 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.1 | |||||
Shareholder Yield % | -14.62 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -542.69 | |||||
Net Margin % | -529.02 | |||||
FCF Margin % | -600.22 | |||||
ROE % | -127.6 | |||||
ROA % | -102.33 | |||||
ROIC % | -650.95 | |||||
3-Year ROIIC % | -9333.28 | |||||
ROC (Joel Greenblatt) % | -2952.68 | |||||
ROCE % | -114.89 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 20.33 | |||||
PB Ratio | 5.27 | |||||
Price-to-Tangible-Book | 5.29 | |||||
EV-to-EBIT | -3.69 | |||||
EV-to-EBITDA | -3.76 | |||||
EV-to-Revenue | 17.68 | |||||
EV-to-FCF | -3.28 | |||||
Price-to-Net-Current-Asset-Value | 5.58 | |||||
Price-to-Net-Cash | 7.5 | |||||
Earnings Yield (Greenblatt) % | -27.14 | |||||
FCF Yield % | -27.73 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Lytix Biopharma AS Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil kr) | 14.443 | ||
EPS (TTM) (kr) | -1.852 | ||
Beta | -0.7 | ||
Volatility % | 80.15 | ||
14-Day RSI | 31.73 | ||
14-Day ATR (kr) | 0.815836 | ||
20-Day SMA (kr) | 7.365 | ||
12-1 Month Momentum % | 40.46 | ||
52-Week Range (kr) | 4.6 - 15 | ||
Shares Outstanding (Mil) | 49.61 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Lytix Biopharma AS Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Lytix Biopharma AS Stock Events
Event | Date | Price(kr) | ||
---|---|---|---|---|
No Event Data |
Lytix Biopharma AS Frequently Asked Questions
What is Lytix Biopharma AS(OSL:LYTIX)'s stock price today?
When is next earnings date of Lytix Biopharma AS(OSL:LYTIX)?
Does Lytix Biopharma AS(OSL:LYTIX) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |